Five stages of evolving beta-cell dysfunction during progression to diabetes - PubMed (original) (raw)
Review
Five stages of evolving beta-cell dysfunction during progression to diabetes
Gordon C Weir et al. Diabetes. 2004 Dec.
Abstract
This article proposes five stages in the progression of diabetes, each of which is characterized by different changes in beta-cell mass, phenotype, and function. Stage 1 is compensation: insulin secretion increases to maintain normoglycemia in the face of insulin resistance and/or decreasing beta-cell mass. This stage is characterized by maintenance of differentiated function with intact acute glucose-stimulated insulin secretion (GSIS). Stage 2 occurs when glucose levels start to rise, reaching approximately 5.0-6.5 mmol/l; this is a stable state of beta-cell adaptation with loss of beta-cell mass and disruption of function as evidenced by diminished GSIS and beta-cell dedifferentiation. Stage 3 is a transient unstable period of early decompensation in which glucose levels rise relatively rapidly to the frank diabetes of stage 4, which is characterized as stable decompensation with more severe beta-cell dedifferentiation. Finally, stage 5 is characterized by severe decompensation representing a profound reduction in beta-cell mass with progression to ketosis. Movement across stages 1-4 can be in either direction. For example, individuals with treated type 2 diabetes can move from stage 4 to stage 1 or stage 2. For type 1 diabetes, as remission develops, progression from stage 4 to stage 2 is typically found. Delineation of these stages provides insight into the pathophysiology of both progression and remission of diabetes.
Similar articles
- The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus.
Kahn SE. Kahn SE. Am J Med. 2000 Apr 17;108 Suppl 6a:2S-8S. doi: 10.1016/s0002-9343(00)00336-3. Am J Med. 2000. PMID: 10764844 Review. - Beta-cell adaptation and decompensation during the progression of diabetes.
Weir GC, Laybutt DR, Kaneto H, Bonner-Weir S, Sharma A. Weir GC, et al. Diabetes. 2001 Feb;50 Suppl 1:S154-9. doi: 10.2337/diabetes.50.2007.s154. Diabetes. 2001. PMID: 11272180 Review. - Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin: clinical pathophysiology and natural history of beta-cell dysfunction and insulin resistance.
Mauvais-Jarvis F, Sobngwi E, Porcher R, Riveline JP, Kevorkian JP, Vaisse C, Charpentier G, Guillausseau PJ, Vexiau P, Gautier JF. Mauvais-Jarvis F, et al. Diabetes. 2004 Mar;53(3):645-53. doi: 10.2337/diabetes.53.3.645. Diabetes. 2004. PMID: 14988248 - Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat.
Tokuyama Y, Sturis J, DePaoli AM, Takeda J, Stoffel M, Tang J, Sun X, Polonsky KS, Bell GI. Tokuyama Y, et al. Diabetes. 1995 Dec;44(12):1447-57. doi: 10.2337/diab.44.12.1447. Diabetes. 1995. PMID: 7589853 - Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes.
Carpentier A, Mittelman SD, Bergman RN, Giacca A, Lewis GF. Carpentier A, et al. Diabetes. 2000 Mar;49(3):399-408. doi: 10.2337/diabetes.49.3.399. Diabetes. 2000. PMID: 10868961
Cited by
- Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy.
Lu X, Xie Q, Pan X, Zhang R, Zhang X, Peng G, Zhang Y, Shen S, Tong N. Lu X, et al. Signal Transduct Target Ther. 2024 Oct 2;9(1):262. doi: 10.1038/s41392-024-01951-9. Signal Transduct Target Ther. 2024. PMID: 39353925 Free PMC article. Review. - BAFF neutralization impairs the autoantibody-mediated clearance of dead adipocytes and aggravates obesity-induced insulin resistance.
Lempicki MD, Gray JA, Abuna G, Murata RM, Divanovic S, McNamara CA, Meher AK. Lempicki MD, et al. Front Immunol. 2024 Aug 9;15:1436900. doi: 10.3389/fimmu.2024.1436900. eCollection 2024. Front Immunol. 2024. PMID: 39185417 Free PMC article. - Pancreatic beta cell function and insulin resistance profiles in first-degree relatives of patients with prediabetes and type 2 diabetes.
Herrerías-García A, Jacobo-Tovar E, Hernández-Robles CM, Guardado-Mendoza R. Herrerías-García A, et al. Acta Diabetol. 2024 Aug 16. doi: 10.1007/s00592-024-02352-8. Online ahead of print. Acta Diabetol. 2024. PMID: 39150512 - Tanycytic transcytosis inhibition disrupts energy balance, glucose homeostasis and cognitive function in male mice.
Duquenne M, Deligia E, Folgueira C, Bourouh C, Caron E, Pfrieger F, Schwaninger M, Nogueiras R, Annicotte JS, Imbernon M, Prévot V. Duquenne M, et al. Mol Metab. 2024 Sep;87:101996. doi: 10.1016/j.molmet.2024.101996. Epub 2024 Jul 22. Mol Metab. 2024. PMID: 39047908 Free PMC article. - Effect of transgenerational diabetes via maternal lineage in female rats.
Quintanilha Gallego F, Barco VS, Sinzato YK, Paula VG, de Souza MR, Lopes da Cruz L, Roy S, Corrente JE, Damasceno DC. Quintanilha Gallego F, et al. Heliyon. 2024 May 10;10(10):e31049. doi: 10.1016/j.heliyon.2024.e31049. eCollection 2024 May 30. Heliyon. 2024. PMID: 38803977 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical